Small Molecule API Market to Surpass US$ 274.9 Billion by 2026

Global Small Molecule API Market, by API Type (Artificial, and Natural), by Category (Analgesic, Anesthetics, Anticonvulsants, Antimetabolites, Antibacterial, Alkylating Agents, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 126.6 billion in 2017, and is projected to exhibit a CAGR of 9.1% over the forecast period (2018 – 2026).

Strong research and development in API by market players to augment the market growth Key players in the market are focused on research and development in order to develop novel products to address the critical and unmet needs of patients. For instance, according to India Brand Equity Foundation (IBEF), investment in research and development by India-based pharmaceutical companies increased (in term of sales) from 5.3% to 8.5% from 2012 to 2018. Similarly, as per U.S. Food and Drug Administration (FDA), in March 2016, there were around 37 drugs in clinical development for treating serious bacterial infections. These drugs are intended to be primarily launched in the U.S. Moreover, increasing prevalence of various types of cancers worldwide is expected to boost the market growth. International Agency for Research on Cancer published the GLOBOCAN 2018 report, which focuses on geographic variability of cancer incidence and mortality rate across 20 world regions. The report projected 18.1 million new cancer cases (17.0 million excluding non-melanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding non-melanoma skin cancer) in 2018.

Browse 34 Market Data Tables and 23 Figures spread through 261 Pages and in-depth TOC on ‘Small Molecule API Market’- Global Forecast to 2026, by API Type (Artificial, and Natural), by Category (Analgesic, Anesthetics, Anticonvulsants, Antimetabolites, Antibacterial, Alkylating Agents, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the small molecule API market, click the link below:

https://www.coherentmarketinsights.com/market-insight/small-molecule-api-market-2423

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. In October 2017, CordenPharma announced acquisition of Pfizer Inc., a manufacturing facility of API Hospira in Colorado, U.S. This acquisition strengthened the CordenParma’s position, as a leading Contract Development & Manufacturing Organization (CDMO).

Key Takeaways of the Small Molecule API Market:

• The global small molecule API market is expected to exhibit a CAGR of 9.1% over the forecast period, owing to increasing prevalence of cancer and other diseases, extensive research and development for API production and expansion strategies by the market players. In October 2016, Cambrex Corporation acquired the 35,000-square-foot High Point site, formerly owned by PharmaCore
• Among API type, the artificial segment held a dominant position in the small molecule API market in 2018, owing to high prevalence of chronic pain diseases worldwide
• Among Category, the analgesic segment hold a dominant position in the small molecule API market in 2018, as the majority of recent generics launches are in form of sublingual films used in treatment of opioid dependence.
• Key players operating in the global small molecule API market include, Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.